The company said it now expects full year total sepsis and related product revenue of $9.5M-$10.5M, representing growth of 13% to 25%, compared to 2022. FY23 revenue consensus $10.27M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TTOO:
- T2 Biosystems Announces Second Quarter 2023 Financial Results
- T2 Biosystems options imply 96.9% move in share price post-earnings
- Unusually active option classes on open August 7th
- TTOO Earnings this Week: How Will it Perform?
- T2 Biosystems receives extension to comply with Nasdaq listing requirements